Trial Profile
Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms RIVe-CLL/SLL
- 01 Nov 2021 Status changed from recruiting to withdrawn prior to enrolment due to slow accrual.
- 12 Oct 2020 Status changed from not yet recruiting to recruiting.
- 18 Sep 2020 Planned initiation date changed from 31 Aug 2020 to 30 Sep 2020.